

**Vaccines and Related Biological Products  
Advisory Committee October 26, 2021 Meeting  
Presentation**

Individuals using assistive technology may not be able to fully access the information contained in this file. For assistance, please send an e-mail to: [ocod@fda.hhs.gov](mailto:ocod@fda.hhs.gov) and include 508 Accommodation and the title of the document in the subject line of your e-mail.



# **Post-Market Active Surveillance of COVID-19 Vaccines in the Pediatric Population in the FDA BEST System**

Vaccines and Related Biological Products Advisory Committee  
October 26, 2021

Hui-Lee Wong, PhD, MSc  
Associate Director for Innovation and Development  
Office of Biostatistics and Epidemiology  
Center for Biologics Evaluation and Research  
US Food and Drug Administration

# Outline




- Background: FDA Biologics and Effectiveness Safety (BEST) System
- Pediatric population in FDA BEST System
- Safety surveillance of children ages 12-15 years and 16-17 years after Pfizer-BioNTech vaccination
- Summary



# **FDA Biologics and Effectiveness Safety (BEST) System**



# FDA CBER Active Surveillance Program





# Pediatric Population by Age in Administrative Claims, FDA BEST System

FDA BEST Partners	Age 0-4 years	Age 5-11 years	Age 12-15 years	Age 16-17 years
Blue Health Intelligence®	2,534,214	2,521,796	1,719,844	892,165
CVS Health	1,065,238	1,507,802	969,471	507,637
HealthCore	1,242,325	1,832,048	1,219,367	641,236
Optum	1,020,020	1,362,267	891,228	461,513
<b>Total</b>	<b>5,861,797</b>	<b>7,223,913</b>	<b>4,799,910</b>	<b>2,502,551</b>

Pediatric population: Number of enrollees ever enrolled since 12/11/2020 to date of data cutoff (Blue Health Intelligence®: 6/30/2021, CVS Health: 7/31/2021, HealthCore: 8/5/2021, Optum: 9/18/2021)



# Estimated Percent Coverage of US Population by Age in Administrative Claims, FDA BEST System

	<b>Age 0-4 years</b>	<b>Age 5-11 years</b>	<b>Age 12-15 years</b>	<b>Age 16-17 years</b>
<b>Total Across Data Partners*</b>	5,861,797	7,223,913	4,799,910	2,502,551
<b>Census Estimate of US Population (2020)</b>	19,301,292	28,384,878	16,783,176	8,352,767
<b>Estimated Percent Coverage of US Population</b>	<b>30.4%</b>	<b>25.5%</b>	<b>28.6%</b>	<b>30.0%</b>

\*Number of enrollees ever enrolled since 12/11/2020 to date of data cutoff (Blue Health Intelligence®: 6/30/2021, CVS Health: 7/31/2021, HealthCore: 8/5/2021, Optum: 9/18/2021)



# Pediatric Population in Pediatric Electronic Health Records, FDA BEST System

## PEDSnet

- Electronic Health Records
- 8 Children's Hospital Health Systems
- Covers over 7 million children; ~ 1-2 million annually
  - Jan 1, 2020 - Dec 31, 2020:
    - 1.6 million patients with at least 1 encounter, aged 0-17 years





# Pfizer-BioNTech COVID-19 Vaccine Doses in Ages 12-17 Years, FDA BEST System



FDA BEST Partners	Total*	
	Age 12-15 years	Age 16-17 years
Optum	405,534	209,091
HealthCore	406,107	233,677
<b>Total</b>	<b>811,641</b>	<b>442,768</b>

\*First, Second and Third or Unknown /unspecified doses  
Data through 8/5/2021 (HealthCore), 9/18/2021 (Optum)



# Near Real-Time Safety Surveillance of COVID-19 Vaccines, FDA BEST System

These potential adverse events of special interest have not been associated with COVID-19 vaccines based on pre-authorization evidence

Acute myocardial infarction	Bell's Palsy	Narcolepsy
Anaphylaxis	Encephalomyelitis	Non-hemorrhagic Stroke
Appendicitis	Guillain-Barré syndrome	Pulmonary Embolism
Disseminated intravascular coagulation	Hemorrhagic Stroke	Transverse Myelitis
Deep Vein Thrombosis	Myocarditis/Pericarditis	Immune thrombocytopenia
	Thrombosis with Thrombocytopenia	



# Near Real-Time Surveillance of Pfizer-BioNTech COVID-19 Vaccines in 12-64 years, FDA BEST System

Adverse Events of Special Interest	Risk Window (days)	Safety Signal During Testing	
		Optum	HealthCore
Acute Myocardial Infarction	1-28	No	No***
Anaphylaxis	0-1	Yes	Yes
Appendicitis	1-42	No	No
Bell's Palsy	1-42	No	No
Common Thromboses* with Thrombocytopenia	1-28	No	No
Unusual Site Thromboses** with Thrombocytopenia Syndrome	1-28	No	No
Deep Vein Thrombosis	1-28	No	No
Disseminated Intravascular Coagulation	1-28	No	No
Encephalomyelitis	1-42	No	No
Guillain-Barré Syndrome	1-42	No	No***
Hemorrhagic Stroke	1-28	No	No
Immune Thrombocytopenia	1-42	No	No
Multisystem Inflammatory Syndrome	1-42	No	No
Myocarditis/Pericarditis	1-42	No	No
Narcolepsy	1-42	No	No
Non-Hemorrhagic Stroke	1-28	No	No
Pulmonary Embolism	1-28	No	No
Transverse Myelitis	1-42	No	No***

Data through 8/5 (HCl), 9/18 (Optum)

\*acute myocardial infarction, deep vein thrombosis, pulmonary embolism, hemorrhagic stroke, non-hemorrhagic stroke; \*\* cerebral and abdominal

\*\*\*RCA excludes pediatric population (12-17) due to lack of estimable background rates

# Summary of Active Surveillance of Post-Market Safety Data in Pediatric Population in FDA BEST System



- FDA BEST is monitoring the safety of COVID-19 vaccines in near-real time surveillance
- Observed versus Expected Analyses for pediatric population will be conducted when events sufficiently accrue



# Acknowledgements

## FDA BEST Partners

Acumen

CVS Health

Optum

IQVIA/HealthCore

Blue Health Intelligence®

IBM

PEDSnet, OneFlorida, Explorys, Medstar

RTI

Columbia University/OHDSI

## Federal Partners

CDC, CMS, VA

## FDA

Steven Anderson

Richard Forshee

Azadeh Shoaibi

CBER Surveillance Program

- Cindy Zhou, Patricia Lloyd, Joyce Obidi, Kristin Sepúlveda, Tainya Clarke

Narayan Nair and CBER/OBE/DE

CBER OBE Colleagues

